Extended Anticoagulation After Pulmonary Embolism: A Multicenter Observational Cohort Analysis

Area of Science:

• Cardiology
• Pulmonology
• Hematology

Background:

• Pulmonary embolism (PE) carries long-term risks, necessitating strategies like extended anticoagulation.
• Initial anticoagulant therapy (3-6 months) is standard for acute PE.
• The benefit of extending anticoagulation beyond this initial period requires further investigation.

Purpose of the Study:

• To compare clinical outcomes in patients with PE receiving 2-year extended anticoagulation versus those not receiving it.
• To identify factors associated with the decision to prescribe extended anticoagulation.
• To evaluate the efficacy and safety of extended anticoagulation post-PE.

Main Methods:

• Observational cohort analysis of patients who completed initial anticoagulation for PE.
• Comparison of primary efficacy outcomes (all-cause death or recurrent venous thromboembolism) and safety outcomes (major bleeding).
• Statistical analysis to adjust for confounding factors and identify predictors of extended anticoagulation prescription.

Main Results:

• 858 patients (71.5%) received extended anticoagulation, while 341 (28.5%) did not.
• Extended anticoagulation was associated with younger age, higher-risk PE, normal platelets, and no antiplatelet use.
• The adjusted rate of death or recurrent venous thromboembolism was significantly lower in the extended group (2.1%) compared to the non-extended group (7.7%).
• Major bleeding rates were similar between both groups.

Conclusions:

• Extended oral anticoagulation for approximately 2.5 years after PE offers a net clinical benefit in selected patients.
• Randomized trials are warranted to confirm these findings, particularly in patients with transient provoking factors but residual risk.